A Double-Blind, Placebo-Controlled Trial of Albendazole in HIV-Positive Patients With Intestinal Microsporidiosis
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy (stool frequency) and safety (adverse experiences) of albendazole,
administered for 28 days, compared to placebo and for 62 days in open-label fashion, in
treating intestinal microsporidiosis in HIV-positive patients. To assess the effect of
albendazole on stool volume, weight gain, microsporidial counts in small bowel biopsies, and
on the relationship between microsporidial counts in stool and stool frequency and volume. To
correlate microsporidial counts with the clinical course of microsporidiosis.